- Global Pharma News & Resources

Spinal Cord Injury Pipeline Review, H2 2018 - Therapeutic Analysis of 30 Companies & Drug Profiles -

The "Spinal Cord Injury - Pipeline Review, H2 2018" drug pipelines has been added to's offering.

Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 9, 1, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 14 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Spinal Cord Injury - Overview
  3. Spinal Cord Injury - Therapeutics Development
  4. Spinal Cord Injury - Therapeutics Assessment
  5. Spinal Cord Injury - Companies Involved in Therapeutics Development
  6. Spinal Cord Injury - Drug Profiles
  7. Spinal Cord Injury - Dormant Projects
  8. Spinal Cord Injury - Discontinued Products
  9. Spinal Cord Injury - Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • Asterias Biotherapeutics Inc
  • Athersys Inc
  • BioArctic AB
  • BioAxone BioSciences Inc
  • CSL Ltd
  • CSPC Pharmaceutical Group Limited
  • Hemostemix Inc
  • Histocell SL
  • K-Stemcell Co Ltd
  • Kadimastem Ltd
  • Kolon TissueGene Inc
  • Kringle Pharma Inc
  • Mapreg SAS
  • NervGen Pharma Corp
  • Neuralstem Inc
  • Neuronax SAS
  • New World Laboratories Inc
  • Nipro Corp
  • Pharmicell Co Ltd
  • PixarBio Corp
  • RDD Pharma Ltd
  • ReNetX Bio
  • RespireRx Pharmaceuticals Inc
  • SanBio Inc
  • Stemedica Cell Technologies Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Tumorend LLC
  • Vertex Pharmaceuticals Inc
  • Vicore Pharma AB

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018